If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
The Novo Nordisk Foundation is funding the creation of a cell therapy development and manufacturing facility in Denmark with one of the largest investments in the sector i
UK contract development and manufacturer organisation (CDMO) Oxford Biomedica confirmed this morning it is in talks that could result in the acquisition of rival ABL Europ
Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by "insufficient resources" at the FDA.
Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned wit
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.